ReviewThe Journal of international medical research2026
Pulmonary fibrosis: Emerging targets and novel therapeutics.
Review in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary fibrosis, particularly idiopathic pulmonary fibrosis, is a progressive and fatal interstitial lung disease with limited curative therapies. This narrative review provides a concise overview of emerging molecular targets and novel therapeutic strategies for pulmonary fibrosis, including mesenchymal stem cell therapy and nanomaterial-based inhalation systems, focusing on their mechanisms, preclinical evidence, and clinical potential. We highlight critical challenges in translating preclinical discoveries into clinical benefit, such as animal model limitations and patient heterogeneity, and outline future research priorities. Notably, this review is not a systematic review; it does not include formal meta-analysis or a comprehensive literature search following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, which may have introduced selection bias. Thus, findings should be interpreted with appropriate caution.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.